Literature DB >> 22491238

Evaluation of therapeutic effects and pharmacokinetics of antibacterial chromogenic agents in a silkworm model of Staphylococcus aureus infection.

T Fujiyuki1, K Imamura, H Hamamoto, K Sekimizu.   

Abstract

The therapeutic effect of dye compounds with antibacterial activity was evaluated in a silkworm model of Staphylococcus aureus infection. Among 13 chromogenic agents that show antibacterial activity against S. aureus (MIC = 0.02 to 19 μg/mL), rifampicin had a therapeutic effect. The ED(50) value in the silkworm model was consistent with that in a murine model. Other 12 dyes did not increase survival of the infected silkworms. We examined the reason for the lack of therapeutic efficacy. Amidol, pyronin G, and safranin were toxic to silkworms, which explained the lack of therapeutic effects. Fuchsin basic and methyl green disappeared quickly from the hemolymph after injection, suggesting that they are not stable in the hemolymph. Although coomassie brilliant blue R250/G250, cresyl blue, and nigrosin showed no toxic effects or instability in the hemolymph, they also did not have a therapeutic effect. The in vitro antibacterial actions of these dyes were inhibited by silkworm plasma or bovine serum albumin and filtration experiments demonstrated that cresyl blue bound to plasma proteins in the silkworm, suggesting that plasma protein binding inhibited the therapeutic efficacy of these four dyes. These findings indicate that drug screening using the silkworm infection model is useful for evaluating toxicity and pharmacokinetics of potential antibiotics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22491238

Source DB:  PubMed          Journal:  Drug Discov Ther        ISSN: 1881-7831


  8 in total

1.  Synergistic effects of vancomycin and β-lactams against vancomycin highly resistant Staphylococcus aureus.

Authors:  Fumiaki Tabuchi; Yasuhiko Matsumoto; Masaki Ishii; Keita Tatsuno; Mitsuhiro Okazaki; Tomoaki Sato; Kyoji Moriya; Kazuhisa Sekimizu
Journal:  J Antibiot (Tokyo)       Date:  2017-02-15       Impact factor: 2.649

2.  D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus.

Authors:  Fumiaki Tabuchi; Yasuhiko Matsumoto; Masaki Ishii; Keita Tatsuno; Mitsuhiro Okazaki; Tomoaki Sato; Kyoji Moriya; Kazuhisa Sekimizu
Journal:  J Antibiot (Tokyo)       Date:  2017-06-07       Impact factor: 2.649

Review 3.  Bacteriophage Therapy for Staphylococcus Aureus Infections: A Review of Animal Models, Treatments, and Clinical Trials.

Authors:  Lucile Plumet; Nour Ahmad-Mansour; Catherine Dunyach-Remy; Karima Kissa; Albert Sotto; Jean-Philippe Lavigne; Denis Costechareyre; Virginie Molle
Journal:  Front Cell Infect Microbiol       Date:  2022-06-17       Impact factor: 6.073

4.  Metabonomic analysis of Bombyx mori (Heterocera: Bombysidae) treated with acetaminophen.

Authors:  W M Yin; X Xu; Y He; G B Wei; Y H Sima; Xu Shi-Qing
Journal:  J Insect Sci       Date:  2014-01-01       Impact factor: 1.857

5.  An invertebrate infection model for evaluating anti-fungal agents against dermatophytosis.

Authors:  Masaki Ishii; Yasuhiko Matsumoto; Tsuyoshi Yamada; Shigeru Abe; Kazuhisa Sekimizu
Journal:  Sci Rep       Date:  2017-09-25       Impact factor: 4.379

6.  In vitro antibacterial activity and in vivo therapeutic effect of Sesbania grandiflora in bacterial infected silkworms.

Authors:  Pimporn Anantaworasakul; Hiroshi Hamamoto; Kazuhisa Sekimizu; Siriporn Okonogi
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

7.  Pharmacokinetics of anti-infectious reagents in silkworms.

Authors:  Hiroshi Hamamoto; Ryo Horie; Kazuhisa Sekimizu
Journal:  Sci Rep       Date:  2019-07-01       Impact factor: 4.379

8.  Serum apolipoprotein A-I potentiates the therapeutic efficacy of lysocin E against Staphylococcus aureus.

Authors:  Hiroshi Hamamoto; Suresh Panthee; Atmika Paudel; Kenichi Ishii; Jyunichiro Yasukawa; Jie Su; Atsushi Miyashita; Hiroaki Itoh; Kotaro Tokumoto; Masayuki Inoue; Kazuhisa Sekimizu
Journal:  Nat Commun       Date:  2021-11-04       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.